Vincent B. Luscombe

Diverse Effects on M₁ Signaling and Adverse Effect Liability within a Series of M₁ Ago-PAMs

Jerri M. Rook, Masahito Abe, Hyekyung P. Cho et al. · ACS Chemical Neuroscience · 2016 · 57 citations

Medicine, Medicinal Chemistry, Pharmacology +16

Discovery of VU0467485/AZ13713945: An M₄ PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia

Michael R. Wood, Meredith J. Noetzel, Bruce J. Melancon et al. · ACS Medicinal Chemistry Letters · 2016 · 54 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Challenges in the development of an M4 PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs

Michael R. Wood, Meredith J. Noetzel, Michael S. Poslusney et al. · Bioorganic & Medicinal Chemistry Letters · 2016 · 42 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +9

Discovery of VU6005649, a CNS Penetrant mGlu_7/8 Receptor PAM Derived from a Series of Pyrazolo[1,5-<i>a</i>]pyrimidines

Masahito Abe, Mabel Seto, Rocco G. Gogliotti et al. · ACS Medicinal Chemistry Letters · 2017 · 35 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

Discovery of <i>N</i>-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation

Andrew S. Felts, Alice L. Rodriguez, Anna L. Blobaum et al. · Journal of Medicinal Chemistry · 2017 · 30 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14